U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H32O13S
Molecular Weight 656.654
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENIPOSIDE

SMILES

COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7

InChI

InChIKey=NRUKOCRGYNPUPR-QBPJDGROSA-N
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1

HIDE SMILES / InChI
Molecular Formula C32H32O13S
Molecular Weight 656.654
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Teniposide is an inhibitor of topoisomerase II with anti-cancer activity. The drug was approved by FDA under the name Vumon for the treatment of children with acute lymphoblastic leukemia.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Teniposide appears not to cross the blood brain barrier, although in a study in patients with brain tumors, CSF levels of teniposide were higher than CSF levels reported in other studies of patients who did not have brain tumors.

Originator

Approval Year

1992
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
VUMON

Approved Use

Teniposide Injection, in combination with other approved anticancer agents, is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7083.9 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2332 μg × min/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3581097/
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
8.6 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/3297462/
200 mg/m² single, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.9 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/3297462/
100 mg/m² single, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf
155 mg/m² 2 times / week multiple, intravenous
dose: 155 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
20.3 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/4017164
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3581097/
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf
155 mg/m² 2 times / week multiple, intravenous
dose: 155 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
TENIPOSIDE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Other AEs: Infection, Neutropenia...
Other AEs:
Infection (grade 5, 1 patient)
Neutropenia (grade 4, 15 patients)
Neutropenia (grade 3, 8 patients)
Neutropenia (grade 1-2, 6 patients)
Anemia (grade 3, 4 patients)
Anemia (grade 1-2, 20 patients)
Thrombocytopenia (grade 3, 3 patients)
Thrombocytopenia (grade 1-2, 8 patients)
Infection (grade 3, 4 patients)
Infection (grade 1-2, 1 patient)
Fever (grade 1-2, 2 patients)
Nausea (grade 3, 1 patient)
Nausea (grade 1-2, 19 patients)
Vomiting (grade 3, 1 patient)
Vomiting (grade 1-2, 8 patients)
Hyponatremia (grade 4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Other AEs: Myelosuppression, Anaphylactic reaction...
Other AEs:
Myelosuppression (severe)
Anaphylactic reaction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Infection grade 1-2, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Nausea grade 1-2, 19 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Fever grade 1-2, 2 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anemia grade 1-2, 20 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 1-2, 6 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Thrombocytopenia grade 1-2, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Vomiting grade 1-2, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Nausea grade 3, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Vomiting grade 3, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Thrombocytopenia grade 3, 3 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anemia grade 3, 4 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Infection grade 3, 4 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 3, 8 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Hyponatremia grade 4, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Neutropenia grade 4, 15 patients
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Infection grade 5, 1 patient
60 mg/m2 5 times / 3 weeks multiple, intravenous
Dose: 60 mg/m2, 5 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 5 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
unhealthy, 64 years (range: 46–83 years)
Health Status: unhealthy
Age Group: 64 years (range: 46–83 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305702
Anaphylactic reaction
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Myelosuppression severe
165 mg/m2 2 times / week multiple, intravenous
Recommended
Dose: 165 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 165 mg/m2, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
inhibitor
2438

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
2052

MRP3
58
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 yes [IC50 64 uM]
likely (co-administration study)
Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions
CYP2C9
2497
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 major
likely (co-administration study)
Comment: see http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf#page=4 for list of interactions
Page: 4.0
MRP3
58
 yes
P-gp
2052
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY547001
https://www.001chemical.com/chem/29767-20-2
3B Scientific (Wuhan) Corp
3B2-1312
http://www.3bsc.com/index/pro_info.php?id=55028
AA Blocks
AA00I5FJ
https://www.aablocks.com/goods/Goods/detail?id=AA00I5FJ
Aaron Chemicals
AR00I67B
http://www.aaronchem.com/29767-20-2
abcr GmbH
AB452154
http://www.abcr.com/shop/en/AB452154
abcr GmbH
AB508784
http://www.abcr.com/shop/en/AB508784
AbMole Bioscience
M3313
http://www.abmole.com/products/teniposide.html
Acadechem
ACDC-030273
http://acadechemical.com/product/1986
Achemo Scientific Limited
AC-63286
http://www.achemo.com/search/?Keyword= 29767-20-2
Achemtek
0104-019659
http://www.achemtek.com/29767-20-2
AHH Chemical co.,ltd
MT-00056
http://www.ahhchemical.com/product/MT-00056.html
AK Scientific, Inc. (AKSCI)
69655
http://www.aksci.com/item_detail.php?cat=69655
Alfa Chemistry
AP29767202
https://reagents.alfa-chemistry.com/product/teniposide-cas-29767-20-2-9410.html
Ambeed
A102576
https://www.ambeed.com/products/29767-20-2.html
Ambinter
Amb16193060
http://www.ambinter.com/reference/16193060
Ambinter
Amb22492542
http://www.ambinter.com/reference/22492542
Angel Pharmatech
AG201104
http://www.angelpharmatech.com/29767-20-2.html
ApexBio Technology
A8532
http://www.apexbt.com/teniposide.html
Ark Pharm
AK326113
http://www.arkpharminc.com/products/29767-20-2.html
Aurora Fine Chemicals LLC
A24.079.230
http://online.aurorafinechemicals.com/info?ID=A24.079.230
Aurum Pharmatech LLC
W-5144
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5144
AvaChem Scientific
2712
http://www.avachem.com/productSearch.asp?2712
Avantor Inc
TCT3109-100MG
https://us.vwr.com/store/product/16815322/teniposide-98-0-by-hplc
Avantor Inc
TCT3109-20MG
https://us.vwr.com/store/product/16815322/teniposide-98-0-by-hplc
BioChemPartner
BCP08940
http://www.biochempartner.com/29767-20-2-BCP08940
BioCrick
BCC3864
http://www.biocrick.com/Teniposide-BCC3864.html
BioCyc
CPD-16755
https://biocyc.org/compound?orgid=META&id=CPD-16755
BioSynth
J-017623
https://www.biosynth.com/en/products/all-products/products/J-017623.html
BLD Pharm
BD152568
http://www.bldpharm.com/products/29767-20-2.html
Boerchem
BC218913
http://www.boerchem.com/?product_36850.html
Chem Scene
CS-1366
http://www.chemscene.com/29767-20-2.html
ChemMol
30108888
http://www.chemmol.com/chemmol/30108888.html
ChemMol
44005778
http://www.chemmol.com/chemmol/44005778.html
ChemMol
49409320
http://www.chemmol.com/chemmol/49409320.html
ChemMol
99059300
http://www.chemmol.com/chemmol/99059300.html
Chemspace
CSSB00116206870
https://chem-space.com/CSSB00116206870
Chemspace
CSSS02495358825
https://chem-space.com/CSSS02495358825
Clearsynth
CS-T-61638
https://www.clearsynth.com/en/CST61638.html
CSNpharm
CSN12049
https://www.csnpharm.com/products/teniposide.html
DC Chemicals
DCAPI1145
http://www.dcchemicals.com//product_show-Teniposide_Vumon_.html
eNovation Chemicals
D480432
http://www.enovationchem.com/productDetails.asp?productID=D480432
Finetech
FT-0601556
http://www.finetechnology-ind.com/prod/detail/pub/29767-20-2.html
Glentham Life Sciences
GP2668
http://www.glentham.com/products/product/GP2668/
Hairui
HR126555
http://www.hairuichem.com/en/product/29767-20-2.html
Lab Network
LN01327320
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01327320
MedChem Express
HY-13761
https://www.medchemexpress.com/Teniposide.html
Molcore
MC547001
https://www.molcore.com/product/29767-20-2
MolPort
MolPort-009-684-460
https://www.molport.com/shop/molecule-link/MolPort-009-684-460
MuseChem
A000506
https://www.musechem.com/product/A000506.html
OChem
5251
http://www.ocheminc.com/index.php?act=psearch&pid=767T202
Smolecule
S548645
http://www.smolecule.com/products/s548645
Smolecule
S752266
https://www.smolecule.com/products/s752266
Synchem UG and Co KG
67400
http://www.synchem.de/chemical_Teniposide.html
TCI (Tokyo Chemical Industry)
T3109
http://www.tcichemicals.com/eshop/en/us/commodity/T3109/index.html
THE BioTek
bt-288052
https://www.thebiotek.com/product/inhibitors/bt-288052
VladaChem
VL277300-1G
https://www.vladachem.com/product.php?products=29767-20-2
Yuhao Chemical
LX2053
http://www.chemyuhao.com/29767-20-2.html
PubMed

PubMed

TitleDatePubMed
Biotechnological aspects of the production of the anticancer drug podophyllotoxin.
2004-10
Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.
2004-09-15
Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
2004-09-14
Kinetics and regulation of cytochrome P450-mediated etoposide metabolism.
2004-09
Quantification of etoposide and etoposide phosphate in human plasma by micellar electrokinetic chromatography and near-field thermal lens detection.
2004-07-01
[Significance of C-reaction protein for differential diagnosis of fever after chemotherapy on children with acute lymphoblastic leukemia].
2004-07
Bone marrow transplantation for therapy-related acute myeloid leukemia in congenital retinoblastoma associated with 13q deletion syndrome.
2004-07
[Primary central nervous system lymphoma: a report of 28 patients].
2004-06
Regulation of DNaseY activity by actinin-alpha4 during apoptosis.
2004-06
[Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
2004-05
Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.
2004-04-15
[Survivin antisense oligonucleotide induces lymphoma cells apoptosis and sensitizes the cells to chemotherapy].
2004-04
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.
2004-03
Cognitive status and quality of life after treatment for primary CNS lymphoma.
2004-02-24
Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2.
2004-01-24
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.
2004
Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.
2004
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
2003-12-15
[Evaluation of efficacy of treatment for 30 children with neuroblastoma].
2003-12
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
2003-12
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
2003-11-17
[Chemosensitivity testing of oral squamous cell carcinomas with teniposide].
2003-11
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
2003-10
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
2003-10
Extraocular retinoblastoma: a 13-year experience.
2003-09-15
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
2003-09-01
Effect of Aplidin in acute lymphoblastic leukaemia cells.
2003-08-18
Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.
2003-08-01
Interactions between antiepileptic and chemotherapeutic drugs.
2003-07
Enhanced production of podophyllotoxin by Podophyllum hexandrum using in situ cell retention bioreactor.
2003-06-07
DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
2003-06
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
2003-05
Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.
2003-04-17
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
2003-04-15
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
2003-03-15
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
2003-03-15
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.
2003-03-10
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
2003-02-24
Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer.
2003-01-13
Recent advances in traditional plant drugs and orchids.
2003-01
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
2003-01
Successful paternity with microassisted fertilization after total body irradiation-based conditioning for autologous bone marrow transplantation.
2003
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
2003
[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
2002-12
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
2002-11-01
[Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
2002-11
The role of caspases 9 and 9-short (9S) in death ligand- and drug-induced apoptosis in human astrocytoma cells.
2002-10-15
Platinum drugs in the treatment of non-small-cell lung cancer.
2002-10-07
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
2002-09
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
2002-08
Patents

Patents

JP2005507376A
6
JP2005519871A
30
JP2005520795A
26
JP2006528196A
42
JP2007506647A
5
JP2008519861A
32
JP2009513567A
66
JP2010506837A
76
JP2011522802A
31
JP4776843B2
17
JP4787165B2
104

Sample Use Guides

In Vivo Use Guide
Teniposide Injection must be diluted with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, to give final teniposide concentrations of 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, or 1.0 mg/mL. It is recommended that the teniposide solution be administered over at least a 30- to 60-minute period.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/3469013
Human leukemic cell line were treated with teniposide for 48 h and the cell growth was inhibited by 50% at 48 nM.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:33:27 GMT 2025
Edited
by admin
on Wed Apr 02 07:33:27 GMT 2025
Record UNII
957E6438QA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENIPOSIDE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
VUMON
Preferred Name English
TENIPOSIDE [USP MONOGRAPH]
Common Name English
teniposide [INN]
Common Name English
TENIPOSIDE [VANDF]
Common Name English
4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-2-THENYLIDENE-.BETA.-D-GLUCOPYRANOSIDE)
Common Name English
TENIPOSIDE [ORANGE BOOK]
Common Name English
Teniposide [WHO-DD]
Common Name English
TENIPOSIDE [USP-RS]
Common Name English
TENIPOSIDE [IARC]
Common Name English
TENIPOSIDE [MI]
Common Name English
NSC-122819
Code English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-9-((4,6-O-(2-THIENYLMETHYLENE)-.BETA.-D-GLUCOPYRANOSYL)-OXY)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))
Common Name English
TENIPOSIDE [MART.]
Common Name English
VM26
Code English
TENIPOSIDE [HSDB]
Common Name English
VM-26
Code English
TENIPOSIDE [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000176
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
FDA ORPHAN DRUG 883
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
WHO-ATC L01CB02
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
WHO-VATC QL01CB02
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
LIVERTOX NBK548102
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
NDF-RT N0000175609
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
NCI_THESAURUS C1331
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
Code System Code Type Description
MERCK INDEX
m10558
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY Merck Index
RXCUI
10362
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY RxNorm
NSC
122819
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
SMS_ID
100000082949
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
CHEBI
75988
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL452231
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
PUBCHEM
452548
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
RS_ITEM_NUM
1643736
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
NCI_THESAURUS
C857
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023638
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
HSDB
6546
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
DRUG CENTRAL
2590
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
IUPHAR
6843
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
FDA UNII
957E6438QA
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
MESH
D013713
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
ECHA (EC/EINECS)
249-831-2
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
DRUG BANK
DB00444
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
EVMPD
SUB10895MIG
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
WIKIPEDIA
TENIPOSIDE
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
INN
3836
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
CAS
29767-20-2
Created by admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
PRIMARY
Related Record Type Details
Structure of TENIPOSIDE CATECHOL
METABOLITE -> PARENT
Structure of TENIPOSIDE ORTHOQUINONE
METABOLITE -> PARENT
Related Record Type Details
Structure of THIOPHENE-2-CARBOXALDEHYDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LIGNAN P
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DEMETHYLEPIPODOPHYLLOTOXIN DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4'-DEMETHYLEPIPODOPHYLLOTOXIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of TENIPOSIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966